Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
265.68
-3.27 (-1.22%)
Market Cap: 34.27 Bil
Enterprise Value: 33.19 Bil
PE Ratio: 0
PB Ratio: 1,062.72
GF Score: 78/100 Alnylam Pharmaceuticals Inc at Evercore ISI HealthCONx Virtual Conference Transcript
Nov 30, 2021 / 02:40PM GMT
Release Date Price:
$183.8
(+1.69%)
Maneka Mirchandaney
Evercore ISI Institutional Equities, Research Division - Analyst
Awesome. Hi, everyone. This is Maneka Mirchandaney from the Evercore ISI biotech team. Very, very thrilled to be here with Alnylam for our next fireside chat at a very exciting time for the company. From the team, we've got Yvonne Greenstreet, who's current President and COO and incoming CEO. So thank you for joining.
Questions & Answers
Maneka Mirchandaney
Evercore ISI Institutional Equities, Research Division - Analyst
And Yvonne, to start, it must be such an exciting time for you. Also, I just want to say how awesome it is to have another female CEO at a leading biotech. But maybe to start, just give us a quick sense for what you've been focused on at Alnylam since you joined in 2016.
Yvonne L. Greenstreet
Alnylam Pharmaceuticals, Inc. - President, COO & Director
Yes, that's great. Thanks, Maneka. And look, it's a pleasure to be here, and thank you so much for having me. It is a real honor to be taking over as
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot